Autonomic nervous system drugs

A mechanism-based inactivator of human CYP2B6 (Ki = 5.6 &microM IC₅₀ = 5.1 &microM) with potent selectivity for CYP2B6 over other CYP450 isoforms.

A mechanism-based inactivator of human CYP2B6 (Ki = 5.6 &microM IC₅₀ = 5.1 &microM) with potent selectivity for CYP2B6 over other CYP450 isoforms.

2-PHENYL-QUINOLIN-4-YLAMINE-

2-Pyridinecarboxaldehyde has been used:• To synthesize chitosan based bifunctionalized adsorbent. • In the aldol addition reaction with pyruvate in the presence of 2-keto-3-deoxy-6-phosphogluconate aldolase (KDPG) catalyst to form

2-Pyridinecarboxaldehyde has been used:• To synthesize chitosan based bifunctionalized adsorbent. • In the aldol addition reaction with pyruvate in the presence of 2-keto-3-deoxy-6-phosphogluconate aldolase (KDPG) catalyst to form

2-Pyridinecarboxaldehyde has been used:• To synthesize chitosan based bifunctionalized adsorbent. • In the aldol addition reaction with pyruvate in the presence of 2-keto-3-deoxy-6-phosphogluconate aldolase (KDPG) catalyst to form

2-Pyridinethioamide

2-Pyridinol 1-oxide (HOPO) is a peptide coupling agent used as a subsititue for HOBt. It can form stable chelate complexes with transition metal ions.

2-Pyridinol 1-oxide (HOPO) is a peptide coupling agent used as a subsititue for HOBt. It can form stable chelate complexes with transition metal ions.

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.